

























	Three Months Ended March 29, 2026
(In millions)	North America		EMEA		China		JPAC		Latin America		Total
Total revenues	$	328.9	$	92.5	$	63.5	$	70.0	$	64.9	$	619.8

Less (1):
Cost of sales, excluding amortization of intangibles	114.5		44.6		32.0		41.5		36.7		269.3
Selling, marketing and administrative	44.4		26.6		10.5		12.4		12.0		105.9
Research and development	0.4		0.4		0.7		0.3		0.5		2.3
Other (income) expense, net	0.2		0.8		(0.2)		(0.7)		(0.1)		—
Total segment Adjusted EBITDA	$	169.4	$	20.1	$	20.5	$	16.5	$	15.8	242.3
Reconciliation of segment Adjusted EBITDA
Corporate (2)											(133.6)
Depreciation and amortization											(112.9)
Interest expense, net											(51.1)
Restructuring, integration and other charges											(4.4)




Amortization of deferred cloud computing implementation costs											(8.0)
Employee compensation charges											(5.5)
Loss on investments											(0.9)
EU medical device regulation transition costs (3)											(0.7)
Other adjustments											(4.7)
Loss before income taxes											$	(79.5)
























	Three Months Ended March 30, 2025
(In millions)	North America		EMEA		China		JPAC		Latin America		Total
Total revenues	$	406.7	$	88.9	$	75.0	$	68.1	$	54.1	$	692.8

Less (1):
Cost of sales, excluding amortization of intangibles	128.4		47.3		34.2		37.9		32.1		279.9
Selling, marketing and administrative	43.6		22.9		10.6		12.2		9.8		99.1
Research and development	0.4		0.6		0.9		0.4		0.4		2.7
Other (income) expense, net	—		1.6		—		—		(0.2)		1.4
Total segment Adjusted EBITDA	$	234.3	$	16.5	$	29.3	$	17.6	$	12.0	309.7
Reconciliation of segment Adjusted EBITDA
Corporate (2)											(149.9)
Depreciation and amortization											(107.1)
Interest expense, net											(40.0)
Restructuring, integration and other charges											(16.1)


Amortization of deferred cloud computing implementation costs											(4.3)


Gain on investments											0.3
EU medical device regulation transition costs (3)											(0.2)
Other adjustments											(1.2)
Loss before income taxes											$	(8.8)

(2) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.

(3) Represents incremental consulting costs and R&D manufacturing site costs to align compliance of the Company’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.